Drug delivery, disposition and dynamics (D4)

Drug Delivery, Disposition and Dynamics

The Drug delivery, disposition and dynamics (D4) research teams within the Monash Institute of Pharmaceutical Sciences (MIPS) are designing and developing the next generation of drug delivery systems and anti-infective agents to enhance medicine effectiveness and patient treatment.

See the latest news

Melbourne researchers use cutting-edge technology to produce three new COVID-19 vaccine candidates

Monash University researchers have produced the first known mRNA COVID-19 vaccine candidates in Australia using an advanced technological approach capable of generating vaccines ready for human testing in record time.

8 April, 2020

Professor Nicolas Voelcker named Australian Academy of Technology and Engineering Fellow

Professor Nicolas Voelcker from the Drug Delivery Disposition & Dynamics Theme at the Monash Institute of Pharmaceutical Sciences (MIPS) has been named an Australian Academy of Technology and Engineering Fellow.

23 October, 2019

A/Prof Joe Nicolazzo receives IMPACT grant from FIGHTMND

FightMND has announced a major funding commitment to advance research into Motor Neurone Disease as the fight to find effective treatments and a cure for the disease continues.

16 October, 2019

MIPS maintains top score in 2018 ERA rankings

The Monash Institute of Pharmaceutical Sciences has again received excellent results in the latest Excellence in Research for Australia (ERA) rankings.

17 September, 2019
Representatives of the three PharmAlliance partners: (L-R) Dr Andreia Bruno (Monash), Dr Oksana Pyzik (UCL) and Dr David Steeb (UNC)

PharmAlliance meets at Monash University

PharmAlliance, the research, professional practice and education partnership between the Schools of Pharmacy at Monash University, University College London (UCL) and the University of North Carolina at Chapel Hill (UNC), has held its

17 September, 2019

Faculty success in major Commonwealth grant programs

The Monash Faculty of Pharmacy and Pharmaceutical Sciences has been awarded nearly $20 million dollars in research funding in the recent rounds of grants announced by the National Health and Medical Research Council (“NHMRC”) and the

20 December, 2017
Starpharma logo

MIPS partner, Starpharma, announces positive phase 1 clinical results for DEP® Docetaxel

11 October 2017

Scientists within Professor Chris Porter’s group at the ARC Centre of Excellence for Convergent Bio-Nano Science and Technology at the Monash Institute of Pharmaceutical

11 October, 2017

Monash scientists gain multimillion-dollar NIH grant for ‘superbug’ drug discovery program

August 2017

A world-leading team, led by Professor Jian Li from the Monash Biomedicine Discovery Institute (BDI), has been awarded a multi-million dollar grant

30 August, 2017

Monash University signs licensing deal for novel drug delivery technology

30 August 2017

The Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University today announced the licensing of a lymphatic drug targeting technology platform to clinical-stage biopharmaceutical

30 August, 2017